Pemphigus foliaceus (PF) belongs to the autoimmune blistering diseases of the skin, also including the more prevalent type, pemphigus vulgaris (PV). Autoantibodies primarily target the desmosomal adhesion molecules desmoglein (dsg)1 and 3 and induce intraepithelial split formation. This process, known as acantholysis, clinically presents itself as vesicles and erosions in the epithelium of the skin and mucous membranes, leading to scaling and bleeding. In distinction stands PF, which has autoantibodies solely targeting dsg1, meaning only the skin is affected. Predilection sites are the seborrheic areas of the upper trunk, face and scalp, where puff-pastry like lesions occur due to subcorneal blisterformation.
Current therapeutic approaches involve high dose, systemic corticosteroids, immunoapheresis of circulating autoantibodies and intravenous administration of immunoglobulins, including the anti-CD20-antibody Rituximab. No targeted treatment is established yet. This project aims to asses wether PF has a similar pathomechanism as PV and to identify the role of kinases in it. The human skin organ culture model for PF imitates the formation of intraepidermal split by introducing a specific single-chain variable fragment (scFv). I aim to evaluate the effectiveness of kinase inhibitors in this particular HSOC model for PF.